Q4 25 EPS
$3.08
BEAT +4.85%
Est. $2.94
Q4 25 Revenue
$1.09B
BEAT +1.73%
Est. $1.07B
vs S&P Since Q4 25
-25.9%
TRAILING MARKET
IDXX -20.5% vs S&P +5.4%
Market Reaction
Did IDXX Beat Earnings? Q4 2025 Results
Revenue was $1.09 billion, below the $1.09 billion consensus estimate. EPS was $3.08, above the $2.99 consensus estimate. IDEXX Laboratories reported a 14% increase in revenue for Q4 2025 compared to the same period last year, driven by strong growth… Read more Revenue was $1.09 billion, below the $1.09 billion consensus estimate. EPS was $3.08, above the $2.99 consensus estimate. IDEXX Laboratories reported a 14% increase in revenue for Q4 2025 compared to the same period last year, driven by strong growth in Companion Animal Group (CAG) diagnostics. The company achieved a notable 18% increase in EPS, supported by operating margin expansion and favorable currency impacts. The company projects 2026 revenue to range between $4.63 billion and $4.72 billion, with EPS expected to grow between 9% and 13%. Key growth drivers include the successful launch of IDEXX Cancer Dx for canine lymphoma and the expansion of the IDEXX inVue Dx instrument base.
Key Takeaways
- • Strong CAG Diagnostics recurring revenue growth
- • Expansion of IDEXX inVue Dx instrument base
IDXX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
IDXX Revenue by Segment
With YoY comparisons, source: SEC Filings
IDXX Revenue by Geography
With YoY comparisons, source: SEC Filings
“IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world.”
— Jay Mazelsky, Q4 2025 Earnings Press Release
IDXX Earnings Trends
IDXX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
IDXX EPS Trend
Earnings per share: estimate vs actual
IDXX Revenue Trend
Quarterly revenue: estimate vs actual
IDXX Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $3.41 | $3.47 | +1.74% | $1.14B | +2.88% |
| Q4 25 BEAT | $2.94 | $3.08 | +4.85% | $1.09B | +1.73% |
| Q3 25 BEAT | $3.14 | $3.40 | +8.29% | $1.11B | +3.16% |
| Q2 25 BEAT | $3.30 | $3.63 | +9.97% | $1.11B | +3.95% |
| Q1 25 BEAT | $2.84 | $2.96 | +4.06% | $998.4M | +0.20% |
| Q2 23 BEAT | $2.47 | $2.67 | +8.10% | $943.6M | +0.99% |
| Q1 22 BEAT | $2.26 | $2.27 | +0.44% | $836.5M | -0.38% |